AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

PBLS · NASDAQ · Biotechnology

Parabilis Medicines (PBLS)

Develops Helicon peptides for hard-to-reach intracellular protein targets.

$42.00

Pre-market+1.96 (+4.90%)

At close$40.04(+1.44%)

Watchlist

In millions of USD, except per-share figures

In millions	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	0	0	0	0
Cost of revenue	0	1	0	0
Gross profit	0	−1	0	0
	40	36	47	51
Research & development	34	30	38	39
	6	6	10	12
General & administrative	6	0	10	12
Operating income	−40	−37	−47	−51
	2	2	2	−2
Interest income	1	1	2	4
Interest expense	0	0	0	0
Other non-operating income	−2	0	−2	1
Income before tax	−38	−35	−45	−52
Net income from continuing operations	−38	−35	−45	−52
Net income	−38	−35	−45	−52
EPS, basic	−$23.84	−$0.36	−$34.58	−$2.32
EPS, diluted	−$23.84	−$0.36	−$34.58	−$2.32
Weighted average shares, basic	2	2	2	29
Weighted average shares, diluted	2	2	2	29
EBITDA	−37	−36	−44	−52
Depreciation & amortization	1	1	1	1
EBIT	−38	−37	−45	−52